Autopsy report · NCT00412776

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

“Corporate reasons unrelated to safety and efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year after it had already started.
• Ran for about 2 years 4 months before it stopped.
• 165 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Sesen Bio, Inc.

Sponsor type

Industry

Conditions

Carcinoma, Squamous Cell of Head and Neck; Carcinoma, Squamous Cell; Neoplasms, Squamous Cell; Head and Neck Neoplasms; Mouth Neoplasms; Head and Neck Cancer

Interventions

Proxinium

Participants

165

Sites

122

Countries

Argentina, Brazil, Croatia, France, Germany, Hungary, India, Israel, Italy, Mexico, Poland, Romania and more

Trials that died the same way

• An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
  “Business reasons unrelated to product safety” (81% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (78% match in meaning)
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
  “Not related to safety concerns or lack of efficacy” (72% match in meaning)
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (71% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.